Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus PRISCOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus PRISCOLINE.
IV PERSANTINE vs PRISCOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Priscoline (tolazoline) is a competitive alpha-adrenergic receptor antagonist; also has direct vasodilatory and histamine-like effects, leading to peripheral vasodilation and decreased peripheral vascular resistance.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
10-50 mg subcutaneously or intramuscularly every 4-6 hours; intravenous administration (10 mg slow IV push) reserved for acute vasospastic episodes.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Terminal elimination half-life is approximately 3-4 hours in adults; prolonged in renal impairment.
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Primarily renal excretion of unchanged drug (approximately 90%); minor fecal excretion (<10%).
Category C
Category C
Vasodilator
Vasodilator